Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab Plus Temozolomide in Metastatic Melanoma
NCT01119508Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2010
- Primary completion
- Aug 2016
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ipilimumab, temozolomide in melanoma, sponsored by University of Texas MD Anderson Cancer Center. Started May 2010; status: completed.
02
Drugs
ipilimumabtemozolomide
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01119508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01119508.